The mitochondrial fission inhibitor, the Drp-1 inhibitor, may be a valuable agent as an adjunctive treatment with the conventional therapy after cerebral ischemia from ischemic stroke or other neurological diseases such as traumatic brain injury with brain herniation, subarachnoid hemorrhage with vasospasm, or hypoxic-ischemic encephalopathy after a cardiac arrest condition. This evidence concerns the gene DNM1L and ischemic stroke.